Paul O'brien
About Paul O'brien
Paul O'Brien is an Associate Director of M&A at BridgeBio, where he has worked since 2023. He has a strong academic background with a PhD in Biochemistry and Molecular Biophysics from Columbia University and extensive experience in equity research and strategic analysis within the healthcare sector.
Current Role at BridgeBio
Paul O'Brien serves as the Associate Director of M&A at BridgeBio, a position he has held since 2023. In this role, he is involved in mergers and acquisitions, contributing to the company's strategic growth initiatives. His work is based in the New York City Metropolitan Area.
Previous Experience in Equity Research
Prior to his current role, O'Brien worked at Piper Sandler as an Equity Research Associate for five months in 2020. He also held positions at Roth Capital, where he was an Equity Research Associate focused on biotech from 2018 to 2020. His experience in equity research has provided him with a strong foundation in analyzing healthcare investments.
Background in Healthcare Analysis
O'Brien has significant experience in healthcare analysis, having worked as a Healthcare Associate at Point72 for five months in 2022 and as a Strategic Analyst at Regeneron from 2020 to 2022. These roles have allowed him to develop expertise in evaluating healthcare companies and market trends.
Educational Qualifications
Paul O'Brien earned his Doctor of Philosophy (PhD) in Biochemistry and Molecular Biophysics from Columbia University, where he studied from 2010 to 2018. He also holds a Bachelor's degree in Chemical and Biomolecular Engineering and a Master's degree in Biotechnology, both from the University of Pennsylvania, completed between 2005 and 2010.
Research Experience at Columbia University
During his time at Columbia University, O'Brien worked as a PhD researcher from 2010 to 2018. This role involved conducting advanced research in biochemistry and molecular biophysics, contributing to his extensive knowledge in the field.